Recent Performance Snapshot for TG Therapeutics Stock

TG Therapeutics (TGTX) has drawn fresh attention after a stretch of strong share price performance, with the stock up 0.5% in the latest session and gaining over the past week, month and past 3 months.

At a last close of $50.54, TG Therapeutics now carries a market value of about $7.1 billion, supported by reported revenue of $700.349 million and net income of $461.896 million from its commercial stage biopharmaceutical operations.

For context, TG Therapeutics has seen strong recent momentum, with a 30-day share price return of 27.95% and a 90-day share price return of 68.24%, set against a 1-year total shareholder return of 44.40% that reflects both price moves and any distributions.

If the TG Therapeutics story has you looking across healthcare, it could be a good moment to see what other fast growing opportunities are emerging in areas like neurology and immunology via our specialist healthcare AI stock screener, starting with 40 healthcare AI stocks.

With TG Therapeutics stock posting strong recent returns, investors now face a key question: Is the current price still below what the company could be worth, or has the market already priced in future growth?

Most Popular Narrative: 14% Overvalued

The most followed TG Therapeutics narrative pegs fair value at about $44.43 per share, which sits below the recent $50.54 close and frames the current debate on pricing.

The planned launch of subcutaneous (subcu) BRIUMVI is a significant upcoming catalyst, as it could unlock access to 35–40% of the anti-CD20 MS market segment currently dominated by self-administered therapies, greatly increasing BRIUMVI's addressable market and supporting long-term revenue growth.

Curious what has to happen for that fair value to hold up? The narrative leans heavily on rapid revenue expansion, shifting profit margins, and a richer future earnings multiple. The exact mix of those levers might surprise you.

Result: Fair Value of $44.43 (OVERVALUED)

However, TG Therapeutics still faces concentration risk around BRIUMVI and rising competition in MS therapies, either of which could pressure future revenue assumptions that underpin this narrative.

Another View: Market Pricing Versus TG Therapeutics Fair Ratio

The analyst narrative frames TG Therapeutics stock as about 14% overvalued versus a $44.43 fair value, but the current P/E of 15.5x tells a different story when set against a fair ratio of 21.5x, the US Biotechs average of 16.4x and peers at 17.9x.

If the market moves closer to that higher fair ratio, today’s gap could reflect upside potential rather than excess optimism. The real question is which reference point you trust most for TG Therapeutics.

Next Steps

With mixed signals on TG Therapeutics stock value and future potential, this is a good time to review the full picture and decide where you stand yourself. This includes how the company stacks up on 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond TG Therapeutics stock?

If TG Therapeutics has sharpened your focus, do not stop here. Use the Simply Wall St screener to quickly spot other stocks that match your investing style.

• Target potential mispricings by scanning 44 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their financial profile.
• Prioritize resilience by checking 67 resilient stocks with low risk scores that score well on stability so sudden shocks are less likely to catch you off guard.
• Get ahead of the crowd by reviewing the screener containing 20 high quality undiscovered gems before they are widely talked about by the broader market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.